

The questions below were submitted by three shareholders to the company's website as requested in the Notice of Annual General Meeting, issued on 17th June. Two shareholders asked one question each (questions 1 and 2) whilst one shareholder asked multiple questions (questions 3 – 9).

Q: 1. In view of the poor performance of the share price for sometime, I would like to propose that board remuneration is in future linked to share price performance, and there are no increases until such time as a series of a thresholds are met to be presented to and agreed by the shareholders.

A1 A company's share price is impacted by a number of factors which include global economic conditions which may create uncertainty in stock markets and impact on share prices. These include Brexit, and the current global pandemic, and its economic impacts.

The company issues options to key employees and these are often linked to its share price. If the share price falls below the exercise price these options will be "underwater" and of no value.

Basing salaries on a share price would may not be financially viable (or possible) for the Company as it would lead to increases in costs as share prices rise which may not reflect increases in revenue, and drops in salary when the share price may decrease due to a global crisis, when you want your team to support the company.

Salaries are set by a remuneration committee composed of independent non-executive directors which is recognised as good corporate governance. Non-executive directors have not had a salary increase in the last two years and executive director salaries are generally below those of similar size companies.

Q2:. Could you please confirm what are the total human resources dedicated to R & D

A2: OptiBiotix has one employee dedicated to R&D and six employees in total. It has a number of contracts with universities around the world to support post docs and PhD students in its development and human studies. The Company also works with global corporate partners on open innovation projects to share costs and support product and application development.

Q3: In May 2018 Optibiotix raised funds, in order "to list SlimBiome as an own label or branded product in one or more major retailers requires funds to support upfront manufacturing and stocking costs." This did not happen until 18 months later in December 2019 with H&B. The latest fund raise in April 2020 was to take advantage of a "window of opportunity" for China, India and the USA. A window of opportunity usually means a short period of time. As of today 01/07/20 no announcements have been made. How should shareholders interpret a "window of opportunity" in this case"? Up to 18 months like last time

A3: The Company announced a deal with Pierce Asia on 5 May 2020, around two weeks after the fund raise, to manufacture, develop, and sell a wide range of finished products to China and Hong Kong. In the same month it announced deals with Smart for Life to take SlimBiome® technology in Smart For Life cookies into [Walmart](#) in the USA and [Costco](#) in Canada and Evolution 18 to take gummies into Walmart. The Company has not yet announced a deal for India. We also export SlimBiome to Australia as part of deal with OptiPharm, who own Optislim, the No. 1 Australian weight management brand.

Q4: Why did the Co fail to update to promote sweetbiotix in the Annual Report. How to Directors feel knowing some investors will have sold with this lack of any update, especially compared to the updates the year preceding AR. Is the Co trying to attract new investors in or not?

A4: OptiBiotix updated shareholders on its corporate discussions and manufacturing scale up plans SweetBiotix on 17 April 2020, approximately one month before releasing the annual report. There was no further update to report on SweetBiotix and so it was not included in the annual report. The Company spoke to its major shareholders following the annual report including institutions and private client brokers and a number of retail investors. finnCap, the Company's broker made similar calls. There was no evidence to support the questioners supposition that investors sold due to the fact SweetBiotix was not mentioned in the annual report. The Company is not looking to raise funds and has no immediate plans to attract new investment.

Q5. Why does the Company have so many advisors with resulting in no tangible marketing of the Company?

A5: The Company has the appropriate number of advisors required to fulfil its AIM obligations. The Company is seen as a company that communicates more than the vast majority of AIM companies with around 30 regulatory news announcements and over 20 videos or podcasts per year.

Q6. Why is the Co allowing faslo figures to be out in the Market. Do these false figures indirectly benefit the Board and reduce the risk of investors selling. The Co has clearly stated they do not give forecasts as Investors need accurate information, bit in reality have facilitated false figures being available to investors, many of whom are not aware they have not come from the Company. For the record I think its shameful on the Board that this situation has arisen

A6: It is difficult to understand this question as the questioner states the Company does not provide forecasts and then raises a question about "false figures" which would suggest a forecast.

If the reference is to the Goetz analysts report all releases of the report have included a statement which states '*Please note that this Equity Research publication is for Institutional Investor / Professional Investor use only and is not intended for Retail / Private client use. Any opinions, estimates or forecasts regarding OptiBiotix Health Plc's performance made by goetzpartners securities Limited analysts are theirs alone and do not represent opinions, forecasts or predictions of OptiBiotix Health Plc or its management*'

Q7: If the Company cannot forecast then how is it budgeting and planning?

A7: The Company has internal projections for budgeting and planning purposes.

Q8: Why do the Board not issue forecasts for confirmed orders and upgrade as time passes. Is this because they are pathetically low?

A8: The Company issues half yearly and annual reports as required by the AIM Rules. These show rapid year on year growth. The Company also provides regular trading and commercial updates via RNSs, followed up by interviews and director's comments. The Company complies with its obligations under the AIM Rules to provide the market with all relevant information on a timely basis. It would be unusual for a publicly listed company to regularly report orders from its partners and would potentially impact on the relationship it has with existing and future partners.

Q9. Is the proposed Nasdaq listing a smoke screen that the Co is failing to attract any new investors in UK or European Markets (see forecast questions)

A9: The company attracted a number of new institutional investors in its recent placing. This was reported in its RNS of 17 April 2020.